Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections

Background: Because of their similar modes of transmission, thesimultaneous infection of viral hepatitis and human immunodeficiencyvirus are increasingly seen as a big problem related to human health.Aims: To determine the drug mutations in hepatitis B virus and/or hepatitis C virus co-infected human immunodeficiency virus-1patients in Turkey.Study Design: Retrospective cross-sectional study.Methods: The present study was conducted between 2010 and 2017.HBsAg, anti-hepatitis C virus, and anti-human immunodeficiencyvirus were tested with ELISA. All anti-human immunodeficiencyvirus positive results by ELISA were verified for anti-humanimmunodeficiency virus positivity by a Western blot test, and Antihuman immunodeficiency virus positive patients with HBsAg and/oranti-hepatitis C virus positivity were included in the study. Subtypingand genotypic resistance analyses were performed by populationsequencing of the viral protease and reverse transcriptase regions ofthe human immunodeficiency virus-1 pol gene.Results: We detected 3896 human immunodeficiency virus-1 positivepatients whose sera were sent from numerous hospitals across thecountry to our polymerase chain reaction unit for detection of drugresistance mutations and whose molecular laboratory tests werecompleted. Viral hepatitis co-infections were detected in 4.3% (n=170)of patients. Hepatitis B virus and hepatitis C virus co-infection wereobserved in 3.2% and 0.5% of all human immunodeficiency virus-1infected patients, respectively. The major human immunodeficiencyvirus-1 subtype detected was group M, subtype B (62.9%). However,13.5% of drug resistance mutation motifs were found in humanimmunodeficiency virus-1 genomes of patients included in the study.Conclusion: Due to similar transmission routes, HIV1 patients are atrisk of hepatitis B and C virus co-infection. However, antiretroviraldrug resistance mutation model is similar to patients with hepatitisnegative.

PDF

___

1. World Health Organisation. www.who.int/gho/hiv/epidemic_status/en/ 2016.
2. A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://aidsinfo.nih.gov/guidelines on 1/18/2018.
3. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV co- infection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 2014;61:20-33.
4. Chinen J, Shearer WT. Molecular virology and immunology of HIV infection. J Allergy Clin Immunol 2002;110:189-98.
5. UNAIDS. Global AIDS update. Edited by HIV/AIDS JUNPo. Geneva: United Nations; 2016.
6. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 2000;19:237-9.
7. Pinchoff J, Tran OC, Chen L, Bornschlegel K, Drobnik A, Kersanske L, et al. Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co- infection in YC, 2000-2011. Epidemiol Infect 2016;144:3354-64.
8. Rajbhandari R, Jun T, Khalili H, Chung RT, Ananthakrishnan AN. HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. J Viral Hepat 2016;23:820-9.
9. Crowell TA, Berry SA, Fleishman JA, LaRue RW, Korthuis PT, Nijhawanet AE, et al. Impact of hepatitis co-infection on healthcare utilization among persons living with HIV. J Acquir Immune Defic Syndr 2015;68:425-31.
10. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV coinfection. Antiviral Res 2010;85:303-15.
11. Hacettepe University, HIV/AIDS Treatment and Research Centre. Annual Report 2018.
12. International Medicine System (IMS) Health Turkey. www.imshealth.com/ portal/ site/imshealth.
13. Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Ageand region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011;11:337.
14. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6.
15. Ökten A. Etiology of chronic hepatitis, cirrhosis and hepatocellular carcinoma in Turkey. Current Gastroenterol 2003;7:187-91.
16. Sayan M, Akhan S, Sargin F, Yasar K, Cagatay A, Inan D et al. Molecular characterization of HIV-1 in HBV ± HDV/HCV co-infected HIV-1 positive patients in Turkey. Abstracts of the 19th Annual Meeting of the European Society for Clinical Virology, 14th-17th September 2016, Lisbon, Portugal. Abstract no: 17 Presentation at ESCV 2016: Poster 134.
17. Alter MJ. Epidemiology of viral hepatitis and co-infection. J Hepatol 2006;44(1 Suppl):6-9.
18. Kallas E, Huik K, Türk S, Pauskar M, Jõgeda E, Marina Šuninaet al. T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral Immunol. 2016;29(8): 464-470.
19. EACS European AIDS Clinical Society. Guidelines Version 9.0. 2017.
20. Sayan M, Sargin F, Inan D, Sevgi DY. Celikbas AK, Yasar K, et al. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. AIDS Res Hum Retroviruses 2016;32:26-31.
21. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009;4:4724.
22. İnci A, Fincancı M, Soysal F. Evaluation of HIV/HBV Co-Infected Cases. J Clin Anal Med 2015;6:439-42.
23. Akinyemi JO, Ogunbosi BO, Fayemiwo AS, Adesina OA, Obaro M, Kuti MA, et al. Demographic and epidemiological characteristics of HIV opportunistic infections among older adults in Nigeria. Afr Health Sci. 2017;17:315-21.
24. Coffie PA, Tchounga BK, Bado G, Kabran M, Minta DK, Wandeler G, et al. Prevalence of hepatitis B and delta according to HIV-type: a multi-country crosssectional survey in West Africa. BMC Infect Dis 2017;17:466.
25. Noubiap JJ, Aka PV, Nanfack AJ, Agyingi LA, Ngai JN, Nyambi PN. Hepatitis B and C Co-Infections in Some HIV-Positive Populations in Cameroon, West Central Africa: Analysis of Samples Collected Over More Than a Decade. PLoS One. 2015;10:e0137375.
26. Jaquet A, Wandeler G, Nouaman M, Ekouevi DK, Tine J, Patassi A, et al. Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a crosssectional study. J Int AIDS Soc 2017;19:21424.
27. Avanzi VM, Vicente BA, Beloto NCP, Gomes-da-Silva MM, Ribeiro CEL, Tuon FF, et al. Profile of HIV subtypes in HIV/HBV and HIV/HCV coinfected patients in Southern Brazil. Rev Soc Bras Med Trop 2017;50:470-7.
28. Inan D, Sayan M. Molecular epidemiology of HIV-1 strains in Antalya, Turkey. J Int AIDS Soc 2014;17(4 Suppl 3):19684.
29. Trafficking in human beings report of European Commission. https://ec.europa. eu/anti- trafficking/sites/antitrafficking/files/ trafficking_in_human_beings_-_ eurostat_-_2014_edition.pdf.
30. UNHCR, Population Statistics 2016. http://popstats.unhcr.org/en/persons_of_concern https://www.unhcr.org/tr/en/refugees-and-asylum-seekers-in-turkey
31. SPREAD Programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008;22:625-35.